Merck & Co. Inc., of Whitehouse Station, N.J., and Samsung Bioepis Co. Ltd., of Seoul, South Korea, have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type I and type II diabetes.